Dong H. Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dong H. Shin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Chaesik Kim
5 shared publicationsBret A. Hughes
3 shared publicationsMark S. Juzych
3 shared publications- Babak Eliassi-Rad
Cincinnati Eye Institute (A.K.K.), Cincinnati, Ohio USA
2 shared publications Catherine M Birt
2 shared publicationsJianming Ren
Kresge Eye Institute and Wayne State University School of Medicine, Detroit, MI 48201-1423, USA
2 shared publications
Latest Publications
- 1 January 2002
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 133 (1) , 40-47
Comparison of long-term incidence of posterior capsular opacification between phacoemulsification and phacotrabeculectomy
- 1 January 2002
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 133 (1) , 40-47
Comparison of long-term incidence of posterior capsular opacification between phacoemulsification and phacotrabeculectomy
- 1 December 2001
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 132 (6) , 875-880
Risk factors for failure of 5-fluorouracil needling revision for failed conjunctival filtration blebs
- 1 December 2001
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 132 (6) , 875-880
Risk factors for failure of 5-fluorouracil needling revision for failed conjunctival filtration blebs
- 1 June 2001
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 10 (3) , 211-214
Topical Verapamil in Glaucoma Filtration Surgery
Because of the reported antifibroblastic effect of verapamil, a calcium-channel blocker, we investigated the potential benefit of adjunctive topical verapamil in patients undergoing glaucoma filtration surgery. This prospective, double-masked, randomized study included 56 eyes of 56 consecutive patients with chronic open-angle glaucoma undergoing trabeculectomy (primary or surgical revision of failed trabeculectomy), trabeculectomy combined with cataract surgery, or Molteno drainage device implantation. Postoperatively, the treated eyes received verapamil (0.25%) or one drop of placebo four times a day for 1 month in addition to 1% prednisolone four times a day and corticosteroid-antibiotic ophthalmic ointment at bedtime. There were no significant differences in preoperative mean intraocular pressure, mean number of medications, and glaucoma severity between the verapamil and placebo groups. There were also no significant differences between the two groups in filtration success rate, mean intraocular pressure, and mean number of medications on postoperative days 1, 4, or 7 and at postoperative months 1, 2, 3, 4, 5, and 6 (P > 0.05). There was no significant benefit of adjunctive topical verapamil when it was used after trabeculectomy, trabeculectomy combined with cataract surgery, or Molteno drainage device implantation.
- 1 June 2001
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 10 (3) , 211-214
Topical Verapamil in Glaucoma Filtration Surgery
Because of the reported antifibroblastic effect of verapamil, a calcium-channel blocker, we investigated the potential benefit of adjunctive topical verapamil in patients undergoing glaucoma filtration surgery. This prospective, double-masked, randomized study included 56 eyes of 56 consecutive patients with chronic open-angle glaucoma undergoing trabeculectomy (primary or surgical revision of failed trabeculectomy), trabeculectomy combined with cataract surgery, or Molteno drainage device implantation. Postoperatively, the treated eyes received verapamil (0.25%) or one drop of placebo four times a day for 1 month in addition to 1% prednisolone four times a day and corticosteroid-antibiotic ophthalmic ointment at bedtime. There were no significant differences in preoperative mean intraocular pressure, mean number of medications, and glaucoma severity between the verapamil and placebo groups. There were also no significant differences between the two groups in filtration success rate, mean intraocular pressure, and mean number of medications on postoperative days 1, 4, or 7 and at postoperative months 1, 2, 3, 4, 5, and 6 (P > 0.05). There was no significant benefit of adjunctive topical verapamil when it was used after trabeculectomy, trabeculectomy combined with cataract surgery, or Molteno drainage device implantation.
- 1 September 1999
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 117 (9) , 1149-1154
Risk Factors for Early Filtration Failure Requiring Suture Release After Primary Glaucoma Triple Procedure With Adjunctive Mitomycin
Research from JAMA Ophthalmology — Risk Factors for Early Filtration Failure Requiring Suture Release After Primary Glaucoma Triple Procedure With Adjunctive Mitomycin
- 1 September 1999
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 117 (9) , 1149-1154
Risk Factors for Early Filtration Failure Requiring Suture Release After Primary Glaucoma Triple Procedure With Adjunctive Mitomycin
Research from JAMA Ophthalmology — Risk Factors for Early Filtration Failure Requiring Suture Release After Primary Glaucoma Triple Procedure With Adjunctive Mitomycin
- 1 May 1999
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 127 (5) , 511-515
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy
- 1 May 1999
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 127 (5) , 511-515
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy
- 15 June 1998
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 236 (7) , 501-506
Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil
· Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. · Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0 ± 1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. · Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. · Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.
- 15 June 1998
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 236 (7) , 501-506
Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil
· Purpose: To evaluate the long-term effect of adjunctive subconjunctival 5-fluorouracil (5-FU) on the filtration outcome of primary glaucoma triple procedure (PGTP) in primary open-angle glaucoma (POAG) patients. · Methods: Seventy-four POAG patients were randomly assigned to PGTP alone (36 patients) or PGTP with adjunctive subconjunctival 5-FU (5.0 ± 1.3 injections of 5 mg each, total of 24.8 mg) (38 patients). After surgery, the patients were examined at regular intervals for intraocular pressure (IOP), visual acuity, medical therapy requirements, and complications. Surgical success was defined as IOP ≤20 mmHg on postoperative medication ≤1 without additional glaucoma surgery. · Results: Over an average follow-up (±SD) of 45.3 ± 25.0 months, both 5-FU and control groups maintained significant improvement of IOP control and visual acuity. However, there were no statistically significant differences between the 5-FU and control groups with respect to postoperative IOP, number of glaucoma medications, visual acuity outcome, and success rate overall or in selected patients with one or more of the risk factors for filtration failure. · Conclusions: The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 ± 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.
- 1 July 1991
- Published by Elsevier in Ophthalmology
- Vol. 98 (7) , 1075-1078
Additive Effect of 1% Apraclonidine Hydrochloride to Nonselective β-Blockers
- 1 July 1991
- Published by Elsevier in Ophthalmology
- Vol. 98 (7) , 1075-1078
Additive Effect of 1% Apraclonidine Hydrochloride to Nonselective β-Blockers